Paraganglioma Market Is Driven By Increasing Cancer Incidences

Paraganglioma, also known as extra-adrenal pheochromocytoma is a rare neuroendocrine tumor that arises from chromaffin cells of the autonomic nervous system. The tumors are usually functional and secret hormones like catecholamines which can cause high blood pressure, headaches and other symptoms. Paraganglioma can be benign or malignant and occur in various parts of the body like the head and neck region, chest, abdomen and pelvic cavity. For diagnosis, CT or MRI scans are conducted followed by biochemical tests to detect catecholamine levels in blood or urine. Treatment involves surgical removal of tumors along with beta-blockers or alpha-blockers for management of high blood pressure during surgery. In some advanced cases, radiation therapy or chemotherapy may also be recommended.

The rising global prevalence of cancers is a key growth driver for the Paraganglioma Market. According to estimates by World Health Organization (WHO), cancer burden has risen to 18.1 million new cases and 9.6 million cancer deaths in 2018. Additionally, improving access to advanced treatment options and medical insurance coverage in developing nations will also propel the market growth during the forecast period.

Get more Insights on- Paraganglioma Market